Heron Stock Analysis


USD 4.28  0.06  1.42%   

The current price rise of Heron Therapeutics may raise some interest from investors. The stock closed today at a share price of 4.28 on 542,935 in trading volume. The company directors and management may have good odds in positioning the firm resources to exploit market volatility in November. The stock standard deviation of daily returns for 90 days investing horizon is currently 5.76. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Heron Therapeutics partners.
Please check Risk vs Return Analysis.
The Heron Therapeutics stock analysis report makes it easy to digest most publicly released information about Heron Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Heron Stock analysis module also helps to analyze the Heron Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

Heron Stock Analysis Notes

About 129.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 1.54. Some equities with similar Price to Book (P/B) outperform the market in the long run. Heron Therapeutics recorded a loss per share of 2.29. The entity had not issued any dividends in recent years. The firm had 1:20 split on the 13th of January 2014. Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California. Heron Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 302 people. To learn more about Heron Therapeutics call Barry Quart at 858 251 4400 or check out https://www.herontx.com.

Heron Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Heron Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Heron Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Heron Therapeutics is way too risky over 90 days horizon
Heron Therapeutics appears to be risky and price may revert if volatility continues
Heron Therapeutics has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 94.97 M. Net Loss for the year was (227.3 M) with loss before overhead, payroll, taxes, and interest of (90.5 M).
Heron Therapeutics currently holds about 83.54 M in cash with (170.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.81.
Latest headline from www.nasdaq.com: Heron Awaits FDA Decision On HTX-019 - Nasdaq

Heron Therapeutics Upcoming and Recent Events

Earnings reports are used by Heron Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Heron Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report23rd of February 2022
Next Financial Report9th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End23rd of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Heron Therapeutics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Heron Therapeutics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Heron Therapeutics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Heron Therapeutics specific information freely available to individual and institutional investors to make a timely investment decision.
19th of August 2022
Unclassified Corporate Event
10th of August 2022
Financial Statements and Exhibits. Unregistered Sales of Equity Securities. Entry into a Material Definitive Agreement
9th of August 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
30th of June 2022
Financial Statements and Exhibits. Cost Associated with Exit or Disposal Activities
14th of June 2022
Financial Statements and Exhibits. Regulation FD Disclosure
25th of May 2022
Submission of Matters to a Vote of Security Holders
9th of May 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
11th of April 2022
Unclassified Corporate Event

Heron Therapeutics Thematic Classifications

In addition to having Heron Therapeutics stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Cancer Fighters
Public companies from health care and pharmaceutical sectors that are focused on fighting cancer

Heron Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Heron Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Heron Therapeutics backward and forwards among themselves. Heron Therapeutics' institutional investor refers to the entity that pools money to purchase Heron Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
State Street CorpCommon Shares16.3 M45.6 M
Franklin Resources IncCommon Shares11.8 M33 M
Ubs Oconnor LlcCommon Shares10.1 M28.3 M
Blackrock IncCommon Shares8.8 M24.5 M
Baker Bros Advisors LpCommon Shares8.1 M22.7 M
Vanguard Group IncCommon SharesM22.2 M
Jpmorgan Chase CoCommon Shares6.9 M19.2 M
Note, although Heron Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Heron Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 501.17 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Heron Therapeutics's market, we take the total number of its shares issued and multiply it by Heron Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Heron Profitablity

Heron Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Heron Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Heron Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Heron Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Heron Therapeutics' profitability requires more research than a typical breakdown of Heron Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (239.34) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (229.19) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -2.29.

Management Efficiency

The entity has return on total asset (ROA) of (41.97) % which means that it has lost $41.97 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (328.53) %, meaning that it created substantial loss on money invested by shareholders. Heron Therapeutics management efficiency ratios could be used to measure how well heron therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 3rd of October, Heron Therapeutics retains the Downside Deviation of 5.31, risk adjusted performance of 0.1234, and Market Risk Adjusted Performance of 0.2247. Heron Therapeutics technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We were able to interpolate and analyze data for nineteen technical drivers for Heron Therapeutics, which can be compared to its competitors. Please check out Heron Therapeutics variance and potential upside to decide if Heron Therapeutics is priced fairly, providing market reflects its last-minute price of 4.28 per share. Given that Heron Therapeutics has jensen alpha of 0.9411, we strongly advise you to confirm Heron Therapeutics's regular market performance to make sure the company can sustain itself at a future point.

Heron Therapeutics Price Movement Analysis

The output start index for this execution was thirty-two with a total number of output elements of twenty-nine. The MESA Adaptive Moving Average indicator adapts to Heron Therapeutics price movement based on the rate change of phase as measured by the Hilbert Transform Discriminator.

Heron Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Heron Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Heron Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Heron Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Peraza Lisa over two months ago via Macroaxis 
Acquisition by Peraza Lisa of 60902 shares of Heron Therapeutics subject to Rule 16b-3
Peraza Lisa over two months ago via Macroaxis 
Exercise or conversion by Peraza Lisa of 1933 shares of Heron Therapeutics subject to Rule 16b-3
Kimberly Manhard over three months ago via Macroaxis 
Sale by Kimberly Manhard of 1504 shares of Heron Therapeutics
Peraza Lisa over three months ago via Macroaxis 
Exercise or conversion by Peraza Lisa of 1932 shares of Heron Therapeutics subject to Rule 16b-3
Peraza Lisa over six months ago via Macroaxis 
Exercise or conversion by Peraza Lisa of 1933 shares of Heron Therapeutics subject to Rule 16b-3
Dissanaike Sharmila over six months ago via Macroaxis 
Acquisition by Dissanaike Sharmila of 20903 shares of Heron Therapeutics subject to Rule 16b-3
Craig Johnson over six months ago via Macroaxis 
Acquisition by Craig Johnson of 10452 shares of Heron Therapeutics subject to Rule 16b-3
Barry Quart over six months ago via Macroaxis 
Payment of 963 shares by Barry Quart of Heron Therapeutics subject to Rule 16b-3
Peraza Lisa over six months ago via Macroaxis 
Acquisition by Peraza Lisa of 23424 shares of Heron Therapeutics subject to Rule 16b-3
Dissanaike Sharmila over a year ago via Macroaxis 
Heron Therapeutics exotic insider transaction detected
Christian Waage over a year ago via Macroaxis 
Sale by Christian Waage of 300 shares of Heron Therapeutics
Peraza Lisa over a year ago via Macroaxis 
Exercise or conversion by Peraza Lisa of 552 shares of Heron Therapeutics subject to Rule 16b-3

Heron Therapeutics Predictive Daily Indicators

Heron Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Heron Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Heron Therapeutics Forecast Models

Heron Therapeutics time-series forecasting models is one of many Heron Therapeutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Heron Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Heron Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Heron Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Heron shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Heron Therapeutics. By using and applying Heron Stock analysis, traders can create a robust methodology for identifying Heron entry and exit points for their positions.
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California. Heron Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 302 people.

Current Heron Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Heron analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Heron analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
33.0Strong Buy5Odds
Heron Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Heron analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Heron stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Heron Therapeutics, talking to its executives and customers, or listening to Heron conference calls.
Heron Analyst Advice Details

Heron Stock Analysis Indicators

Heron Therapeutics stock analysis indicators help investors evaluate how Heron Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Heron Therapeutics shares will generate the highest return on investment. By understating and applying Heron Therapeutics stock analysis, traders can identify Heron Therapeutics position entry and exit signals to maximize returns.
Quick Ratio1.13
Fifty Two Week Low2.1900
Revenue Growth23.10%
Shares Short Prior Month34M
Average Daily Volume Last 10 Day3.08M
Average Daily Volume In Three Month3.4M
Shares Percent Shares Out27.55%
Gross Margins-87.63%
Short Percent Of Float34.93%
Forward Price Earnings-5.34
Float Shares70.21M
Fifty Two Week High12.7900
Enterprise Value To Ebitda-2.37
Fifty Day Average4.1536
Two Hundred Day Average5.3409
Enterprise Value To Revenue5.35
Please check Risk vs Return Analysis. You can also try Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.

Complementary Tools for analysis

When running Heron Therapeutics price analysis, check to measure Heron Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Heron Therapeutics is operating at the current time. Most of Heron Therapeutics' value examination focuses on studying past and present price action to predict the probability of Heron Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Heron Therapeutics' price. Additionally, you may evaluate how the addition of Heron Therapeutics to your portfolios can decrease your overall portfolio volatility.
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Is Heron Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Heron Therapeutics. If investors know Heron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Heron Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Heron Therapeutics is measured differently than its book value, which is the value of Heron that is recorded on the company's balance sheet. Investors also form their own opinion of Heron Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Heron Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Heron Therapeutics' market value can be influenced by many factors that don't directly affect Heron Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Heron Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Heron Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Heron Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.